Literature DB >> 30740435

An editorial on the TAILOR trial-further support for the addition of cetuximab to FOLFOX-4 in the treatment of RAS wild-type metastatic colorectal cancer.

Joanna Blanco1, Michael Karass1.   

Abstract

Entities:  

Year:  2018        PMID： 30740435      PMCID： PMC6330606          DOI： 10.21037/atm.2018.12.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  10 in total

1.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Authors:  C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski
Journal:  Ann Oncol       Date:  2011-01-12       Impact factor: 32.976

2.  Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.

Authors:  Kjell Magne Tveit; Tormod Guren; Bengt Glimelius; Per Pfeiffer; Halfdan Sorbye; Seppo Pyrhonen; Fridbjorn Sigurdsson; Elin Kure; Tone Ikdahl; Eva Skovlund; Tone Fokstuen; Flemming Hansen; Eva Hofsli; Elke Birkemeyer; Anders Johnsson; Hans Starkhammar; Mette Karen Yilmaz; Nina Keldsen; Anne Berit Erdal; Olav Dajani; Olav Dahl; Thoralf Christoffersen
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

3.  Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study.

Authors:  Gerardo Rosati; Carmine Pinto; Francesca Di Fabio; Silvana Chiara; Ivan R Lolli; Enzo M Ruggeri; Libero Ciuffreda; Raimondo Ferrara; Lorenzo Antonuzzo; Daniela Adua; Patrizia Racca; Domenico Bilancia; Elena Benincasa; Maria Elena Stroppolo; Francesco Di Costanzo
Journal:  J Geriatr Oncol       Date:  2018-02-09       Impact factor: 3.599

Review 4.  Metastatic colorectal cancer: current state and future directions.

Authors:  Marwan G Fakih
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

5.  The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.

Authors:  Chiara Pozzi; Alessandro Cuomo; Ilaria Spadoni; Elena Magni; Alessio Silvola; Alexia Conte; Sara Sigismund; Paola Simona Ravenda; Tiziana Bonaldi; Maria Giulia Zampino; Carlotta Cancelliere; Pier Paolo Di Fiore; Alberto Bardelli; Giuseppe Penna; Maria Rescigno
Journal:  Nat Med       Date:  2016-05-02       Impact factor: 53.440

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Authors:  Timothy S Maughan; Richard A Adams; Christopher G Smith; Angela M Meade; Matthew T Seymour; Richard H Wilson; Shelley Idziaszczyk; Rebecca Harris; David Fisher; Sarah L Kenny; Edward Kay; Jenna K Mitchell; Ayman Madi; Bharat Jasani; Michelle D James; John Bridgewater; M John Kennedy; Bart Claes; Diether Lambrechts; Richard Kaplan; Jeremy P Cheadle
Journal:  Lancet       Date:  2011-06-05       Impact factor: 79.321

8.  Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.

Authors:  Carmine Pinto; Francesca Di Fabio; Gerardo Rosati; Ivan R Lolli; Enzo M Ruggeri; Libero Ciuffreda; Daris Ferrari; Giovanni Lo Re; Giovanni Rosti; Paolo Tralongo; Raimondo Ferrara; Oscar Alabiso; Silvana Chiara; Giovanni P Ianniello; Antonio Frassoldati; Domenico Bilancia; Giovanna A Campanella; Carlo Signorelli; Patrizia Racca; Elena Benincasa; Maria Elena Stroppolo; Francesco Di Costanzo
Journal:  Cancer Med       Date:  2016-10-17       Impact factor: 4.452

9.  Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.

Authors:  Shukui Qin; Jin Li; Liwei Wang; Jianming Xu; Ying Cheng; Yuxian Bai; Wei Li; Nong Xu; Li-Zhu Lin; Qiong Wu; Yunfeng Li; Jianwei Yang; Hongming Pan; Xuenong Ouyang; Wensheng Qiu; Kaichun Wu; Jianping Xiong; Guanghai Dai; Houjie Liang; Chunhong Hu; Jun Zhang; Min Tao; Qiang Yao; Junyuan Wang; Jiongjie Chen; S Peter Eggleton; Tianshu Liu
Journal:  J Clin Oncol       Date:  2018-09-10       Impact factor: 44.544

10.  Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis.

Authors:  Peng Zheng; Chunmin Liang; Li Ren; Dexiang Zhu; Qingyang Feng; Wenju Chang; Guodong He; Lechi Ye; Jingwen Chen; Qi Lin; Tuo Yi; Meiling Ji; Zhengchuan Niu; Mi Jian; Ye Wei; Jianmin Xu
Journal:  J Oncol       Date:  2018-09-16       Impact factor: 4.375
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.